Active Ingredient History
Hydroxyurea is an oral antimetabolite; inhibits ribonucleotide reductase and DNA synthesis. It is used for resistant chronic myeloid leukemia, locally advanced squamous cell carcinomas of the head and neck (excluding lip) in combination with concurrent chemoradiation, and to reduce the frequency of painful crises and the need for blood transfusions in patients with sickle cell anemia with recurrent moderate to severe painful crises. Hydroxyurea, a myelosuppressive agent, is the only effective drug proven to reduce the frequency of painful episodes. It raises the level of HbF and the haemoglobin level. It usually decreases the rate of painful episodes by 50%. It was first tested in sickle cell disease in 1984. It also decreases the rate of ACS episodes and blood transfusions by ~50 % in adults. It was developed as an anticancer drug and has been used to treat myeloproliferative syndromes-leukemia, melanoma, and ovarian cancer. It was approved for use by FDA in adults. Side effects includes neutropenia, bone marrow suppression, elevation of hepatic enzymes, anorexia, nausea, vomiting and infertility. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Anemia, Sickle Cell (approved 1967)
Adrenoleukodystrophy (Phase 2)
Allergy and Immunology (Phase 1/Phase 2)
Anemia (Phase 2)
Anemia, Diamond-Blackfan (Phase 1/Phase 2)
Anemia, Sickle Cell (Phase 4)
Arterial Occlusive Diseases (Phase 2/Phase 3)
Astrocytoma (Phase 3)
beta-Thalassemia (Phase 2/Phase 3)
Bile Duct Neoplasms (Phase 2)
Bone Marrow Failure Disorders (Phase 1/Phase 2)
Brain Neoplasms (Phase 2)
Carcinoma, Adenoid Cystic (Phase 1)
Carcinoma, Basal Cell (Phase 1)
Carcinoma, Mucoepidermoid (Phase 1)
Carcinoma, Squamous Cell (Phase 2/Phase 3)
Carcinoma, Verrucous (Phase 1)
Congenital Bone Marrow Failure Syndromes (Phase 2)
Drugs, Investigational (Phase 4)
Esophageal Neoplasms (Phase 2)
Fibroma (Phase 2)
Gangliosidosis, GM1 (Phase 2)
Glioblastoma (Phase 3)
Glioma (Phase 1)
Gliosarcoma (Phase 2)
Graft vs Host Disease (Phase 1)
Granuloma (Phase 1)
Head and Neck Neoplasms (Phase 2)
Healthy Volunteers (Phase 1)
Hematologic Diseases (Phase 3)
Hematopoietic Stem Cell Transplantation (Phase 2/Phase 3)
Hemochromatosis (Phase 3)
Hemoglobinopathies (Phase 3)
Hemoglobin SC Disease (Phase 2)
HIV Infections (Phase 4)
Hodgkin Disease (Phase 2)
Hypertension, Pulmonary (Phase 1/Phase 2)
Idiopathic Pulmonary Fibrosis (Phase 1/Phase 2)
Immune System Diseases (Phase 1/Phase 2)
Inflammation (Phase 2)
Intestinal Neoplasms (Phase 2)
Iron Overload (Phase 2/Phase 3)
Kidney Diseases (Phase 4)
Laryngeal Neoplasms (Phase 3)
Leukemia (Phase 3)
Leukemia, Myeloid, Acute (Phase 2/Phase 3)
Leukemia, Myeloid, Chronic-Phase (Phase 2)
Leukemia, Promyelocytic, Acute (Phase 3)
Leukodystrophy, Globoid Cell (Phase 2)
Leukodystrophy, Metachromatic (Phase 2)
Liver Neoplasms (Phase 2)
Lung Neoplasms (Phase 1)
Lymphocytosis (Phase 2)
Lymphoma (Phase 2)
Lymphoproliferative Disorders (Phase 2)
Malaria (Phase 3)
Meningioma (Phase 2)
Metabolic Diseases (Phase 2)
Mouth Neoplasms (Phase 3)
Mucolipidoses (Phase 2)
Mucopolysaccharidosis III (Phase 2)
Multiple Sclerosis (Phase 2/Phase 3)
Muscular Atrophy, Spinal (Phase 2/Phase 3)
Myelodysplastic Syndromes (Phase 3)
Myeloproliferative Disorders (Phase 3)
Nasopharyngeal Carcinoma (Phase 3)
Nasopharyngeal Neoplasms (Phase 1)
Neoplasm Metastasis (Phase 1)
Neoplasms ()
Neuroblastoma (Phase 1)
Nose Neoplasms (Phase 2)
Oropharyngeal Neoplasms (Phase 1/Phase 2)
Oxidative Stress (Phase 2/Phase 3)
Pancreatic Neoplasms (Phase 2)
Papilloma, Inverted (Phase 1)
Papillomaviridae (Phase 2)
Papillomavirus Infections (Phase 2)
Paranasal Sinus Neoplasms (Phase 3)
Pharyngeal Neoplasms (Phase 3)
Polycythemia Vera (Phase 3)
Primary Immunodeficiency Diseases (Phase 2)
Primary Myelofibrosis (Phase 3)
Pulmonary Disease, Chronic Obstructive (Phase 1/Phase 2)
Renal Insufficiency, Chronic (Phase 1)
Retinal Diseases (Phase 2)
Risk Factors (Phase 3)
Salivary Gland Neoplasms (Phase 1)
Sandhoff Disease (Phase 2)
Squamous Cell Carcinoma of Head and Neck (Phase 2)
Stomach Neoplasms (Phase 2)
Stroke (Phase 3)
Tay-Sachs Disease (Phase 2)
Thalassemia (Phase 2)
Thrombocythemia, Essential (Phase 4)
Tongue Neoplasms (Phase 1)
Wolman Disease (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
